SCYNEXIS Inc
(STU:135A)
€
1.767
0.039 (2.26%)
Market Cap: 68.81 Mil
Enterprise Value: -3.48 Mil
PE Ratio: 0.97
PB Ratio: 0.99
GF Score: 56/100 SCYNEXIS Inc (STU:135A) Transcripts
- SCYNEXIS Inc Annual Shareholders Meeting TranscriptJun 14, 2023
- Q3 2022 SCYNEXIS Inc Earnings Call TranscriptNov 09, 2022€1.97 (-9.07%)Earnings
- SCYNEXIS Inc Corporate, Commercial and R&D Strategy Update Call TranscriptOct 20, 2022
- Q2 2022 SCYNEXIS Inc Earnings Call TranscriptAug 15, 2022€2.85 (+4.89%)Earnings
- Q1 2022 SCYNEXIS Inc Earnings Call TranscriptMay 12, 2022€1.78 (-2.78%)Earnings
- Q4 2021 SCYNEXIS Inc Earnings Call TranscriptMar 29, 2022€4.18 (-3.24%)Earnings
- SCYNEXIS Inc Corporate Update Call TranscriptFeb 10, 2022
- SCYNEXIS Inc Hospital Pipeline Update and KOL Event - Call TranscriptDec 06, 2021
- Q3 2021 SCYNEXIS Inc Earnings Call TranscriptNov 10, 2021€4.87 (+1.88%)Earnings
- SCYNEXIS Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- SCYNEXIS Inc Corporate Commercial Launch Update Corporate Call TranscriptJun 29, 2021
- SCYNEXIS Inc Announces FDA Approval of Brexafemme As The First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections Corporate Call TranscriptJun 02, 2021
- SCYNEXIS, Inc. - Special Call TranscriptMar 02, 2021
- SCYNEXIS Inc Dr. Marco Taglietti Discusses SCYNEXIS TranscriptAug 19, 2020
- SCYNEXIS Inc Annual Shareholders Meeting TranscriptJul 02, 2020
- SCYNEXIS, Inc. - Special Call TranscriptApr 21, 2020
- SCYNEXIS Inc at Needham Healthcare Conference TranscriptApr 14, 2020
- SCYNEXIS, Inc. - Special Call TranscriptJan 08, 2020
- SCYNEXIS Inc to Discuss the Ibrexafungerp Data Presented at ECCMID 2019 - Conference Call TranscriptApr 15, 2019
- 1